Background: Growing evidence suggests that neuroimmune signaling via Toll-like receptors (TLRs) alters brain circuitry related to alcohol use disorders. Both ethanol (EtOH) exposure and the TLR3 agonist, poly(I:C), increase brain TLR3 expression in neurons and glia. Furthermore, previous studies have shown that cortical TLR3 expression is correlated with lifetime EtOH intake in humans.
T HERE ARE NUMEROUS factors that lead to the development of alcohol use disorders (AUDs), and there is growing evidence that neuroimmune activation may play an important role in all stages of addiction (Coller and Hutchinson, 2012; Crews et al., 2011) . Neuroimmune signaling includes a large number of secreted proteins and their associated receptors, first discovered as immune signaling molecules that through paracrine and autocrine amplification mediate responses to infections and trauma (Crews et al., 2017a; Warden et al., 2016) .
Emerging studies in the brain, which is generally sterile, indicate neuroimmune signals contribute to normal brain development and growth, neuroplasticity, neurodegeneration, and addiction Vetreno, 2014, 2016; Crews et al., 2017a,b) . Toll-like receptors (TLRs) are an integral part of this immune signaling and are activated by a variety of innate immune cells in response to pathogens. Animal studies find ethanol (EtOH) exposure increases expression of neuroimmune genes and human studies find expression of cortical TLRs, particularly TLR3 in frontal cortex, are positively correlated with lifetime EtOH drinking (Crews et al., , 2017b . Recent studies have found endogenous agonists activate these receptors in the brain contributing to changes in gene expression, neurocircuitry, and neurodegeneration (Crews and Vetreno, 2016; Okun et al., 2011) . Interestingly, TLR expression is increased in response to stress, alcohol, and other drugs of abuse in both humans and animals Vetreno, 2014, 2016; Crews et al., 2013; Frank et al., 2015; Hutchinson et al., 2010; Northcutt et al., 2015) . Among TLRs, TLR3 is somewhat unique in signaling specific kinases, inducing interferons and interferon receptors. In addition, both EtOH and TLR3 agonists increase TLR3 expression in neurons and glia (Lawrimore and Crews, 2017 ) that could alter brain circuitry.
Moreover, TLR3 activates glial signaling; an effect that is disrupted by naltrexone, a drug used in the treatment of AUDs Qin and Crews, 2012) . Interestingly, cyclooxygenase 2 (COX2), an enzyme that is rapidly induced in response to immune activation (Appleby et al., 1994) is also increased by TLR3 activation (Lee et al., 2011; Pindado et al., 2007; Symensma et al., 2003) and by both acute and chronic EtOH intake (Knapp and Crews, 1999) . Further, TLR activation can lead to glutamatergic disruptions such as enhanced N-methyl-D-aspartate (NMDA) excitability and ultimately excitotoxicity, an effect also observed in EtOH dependence (for review, see Crews and Vetreno, 2014) . Indeed, mice lacking TLRs do not show EtOH-induced changes in cortical glutamate receptor expression (Montesinos et al., 2016) . Together, this suggests an important interplay between TLR signaling and glutamatergic function following EtOH exposure. This is especially relevant to the present work given that glutamatergic dysregulation can contribute to escalations in EtOH drinking and is a feature of excessive EtOH intake (Hwa et al., 2017) .
To this end, there is interest in understanding the potential contribution of Group II metabotropic glutamate receptors (mGluRs), along with excitatory amino acid transporter 2 also known as solute carrier family 1 member 2 and glutamate transporter 1 (GLT1), for their role in AUDs (Joffe et al., 2018) . These Gi-coupled receptors are located both presynaptically (mGluR2 and mGluR3) and postsynaptically (mGluR3) and modulate glutamate release, in part by preventing excitotoxicity (Cartmell and Schoepp, 2000; Conn and Pin, 1997; Forsythe and Barnes-Davies, 1997; Scanziani et al., 1997; Schoepp, 2001) . Moreover, functional activity of mGluR2/3 receptors in cortical regions has been shown to be altered in EtOH dependence and pharmacological activation of mGluR2/3 can reduce EtOH reinstatement (Kufahl et al., 2011; Sidhpura et al., 2010; Zhao et al., 2006) , and restore sensitivity to alcohol following stress exposure . Further, activation of mGluR2/3 in the nucleus accumbens (Acb) has been shown to decrease EtOH selfadministration and EtOH-seeking behaviors (Griffin et al., 2014) . Moreover, we have recently shown that the insular cortex (IC) and its projections to nucleus accumbens core (AcbC), which are presumed to be predominantly glutamatergic (Leong et al., 2016; Seif et al., 2013) , modulate various aspects of EtOH-related behavior. For example, silencing of IC projections to AcbC decreases self-administration . In addition, sensitivity to an interoceptive EtOH drug cue is enhanced when IC or IC? AcbC projections are chemogenetically silenced (Jaramillo et al., 2017) .
Based on previous work from our laboratory and others, we hypothesized that TLR3 activation induces glutamatergic adaptations in mGluR2/3 in the Acb and IC that contribute to escalations in EtOH self-administration. To this end, the first goal of the present work was to identify and assess changes in the expression of TLRs and cellular markers related to TLR function along with levels of expression of mGluR2/3 in IC and AcbC following treatment with the TLR3 agonist polyinosinic-polycytidylic acid (poly(I:C)). These experiments assessed both immediate changes in expression and persistence of changes 18 days later. Next, we assessed the effects of poly(I:C) on EtOH self-administration and the functional role of mGluR2/3. Together, these experiments lay the groundwork for better understanding how neuroimmune activation, through the actions of TLR3, impacts EtOH self-administration.
MATERIALS AND METHODS

Animals
Adult male Long Evans rats (n = 85) were used for these experiments. Rats used to assess poly(I:C) time course effects (n = 29) were EtOH na€ ıve. Rats used for assessing poly(I:C) effects on EtOH self-administration (n = 16) and the role of mGluR2/3 (n = 40) had an EtOH self-administration history (>5 months). Rats were singlehoused in ventilated cages (Tecniplast, West Chester, PA) with ad libitum food and water. Rats were maintained in a temperature and humidity controlled colony with a 12-hour light/dark cycle (lights on at 07:00). All experiments were conducted during the light cycle. Animals were under continuous care and monitoring by veterinary staff from the Division of Comparative Medicine at UNC-Chapel Hill. All procedures were conducted in accordance with the NIH Guide to Care and Use of Laboratory Animals and institutional guidelines.
Drugs
Ethanol (95% v/v; Pharmco-AAPER, Shelbyville, KY) was diluted in distilled water. Poly(I:C) (GE Healthcare and Life Sciences, Pittsburgh, PA; Lot#QI2122) was dissolved in sterile phosphate-buffered saline (PBS), which was also used for control injections. Poly(I:C) was injected intraperitoneal (IP) at a volume of 1 ml/kg. The mGluR2/3 agonist LY379268 (Tocris Biosciences, Minneapolis, MN) was dissolved in saline which was also used for control injections and was administered IP at a volume of 1 ml/kg.
Apparatus
Self-administration chambers (Med Associates Inc., St. Albans, VT) were individually located within sound attenuating chambers with an exhaust fan to circulate air and mask outside sounds. Chambers were fitted with a retractable lever on the opposite walls (left and right) of the chamber. There was a cue light above each lever and liquid receptacles in the center panels adjacent both levers. Responses on the left (i.e., active) lever resulted in cue light illumination, stimulus tone, and delivery of 0.1 ml of solution across 1.66 seconds via a syringe pump into the left receptacle once the response requirement was met. Responses on the right (inactive) lever had no programmed consequence. The chambers also had infrared photobeams which divided the floor into 4 zones to record general locomotor activity throughout each session.
EtOH Self-Administration Training
Self-administration sessions (30 minutes) took place 5 days per week (M-F) with the active lever on a fixed ratio 2 schedule of reinforcement such that every second response resulted in delivery of EtOH. A sucrose-fading procedure was used in which EtOH was gradually added to the 10% (w/v) sucrose solution. The exact order of exposure was as follows: 2% (v/v) EtOH/10% (w/v) sucrose (2E/ 10S), 5E/10S, 10E/10S, 10E/5S, 15E/5S, 15E/2S, 15E, 15E/2S. Following sucrose fading, sweetened EtOH (15E/2S) was the reinforcer for the remainder of the study. At the end of each session, wells were inspected to ensure that rats had consumed all fluid. A sweetened alcohol reinforcer was used as we find these results in stable alcohol self-administration in these long-term studies Randall et al., 2015 Randall et al., , 2017 .
RNA Extraction and Reverse Transcription Polymerase Chain Reaction
Rats were anesthetized with sodium pentobarbital (100 mg/kg, IP) and transcardially perfused with 0.1 M (PBS, pH: 7.4). IC and Acb tissue was dissected based on the atlas of Paxinos and Watson (1998) and total mRNA extracted from individual samples by homogenization in TRI reagent (Sigma-Aldrich, St. Louis, MO) following the single step method (Chomczynski and Sacchi, 2006) . Total mRNA was reverse transcribed as previously described (Vetreno and Crews, 2012; Vetreno et al., 2013) . SYBER green PCR Master Mix (Life Technologies, Carlsbad, CA) was used for the RT-PCR. The real-time PCR was run with an initial activation for 10 minutes at 95°C, followed by 40 cycles of denaturation (95°C, 15 seconds), annealing/extension (57 to 58°C, 1 minute), and finally a melt curve. The primer sequences are presented in Table 1 . The threshold cycle (CT) of each target product was determined, and the DDCT method was used to calculate the percent change relative to control (CON).
mGluR2/3 Immunohistochemistry
Rats were anesthetized with sodium pentobarbital (100 mg/kg, IP) and transcardially perfused with ice-cold 0.1 M (PBS, pH: 7.4) followed by 4% paraformaldehyde. Brains were collected and stored in 30% sucrose cryoprotectant solution until sectioning. Brains were sliced into 40-lm coronal sections on a freezing microtome. Free-floating sections were rinsed in 0.1M PBS. Inhibition of endogenous peroxidase was achieved with a single 5-minute wash in 30% H 2 O 2 . Sections underwent antigen retrieval in citra buffer for 30 minutes at 70°C and were allowed to cool to room temperature. Sections were incubated in rabbit anti-mGluR2/3 primary antibody (1:1,000; Millipore Sigma 06-676; Burlington, MA) for 48 hours at 4°C. Sections were then incubated in horseradish peroxidase goat anti-rabbit secondary (1:200; Vector Labs, Burlingame, CA) for 1 hour at room temperature. Tissue was treated with Diaminobenzidine (Polysciences, Warrington, PA) and then mounted on slides for imaging. Images were acquired utilizing Olympus CX41 light microscope (Olympus America, Center Valley, PA) and analyzed utilizing Image-Pro Premier image analysis software (Media Cybernetics, Rockville, MD). Immunoreactivity data (mGluR2/3-positive pixels/mm 2 ) were acquired from a minimum of 3 sections/brain region/animal, by an experimenter blind to group assignment, and the data were averaged to obtain a single value per subject. The regions examined were the anterior IC (+2.8 to +1.9 mm) and nucleus AcbC (AP to À2.3 to À1.3). The mGluR2/3 antibody was used to verify mGluR2/3-specific staining in 10 lg of brain tissue from the dorsal medial striatum (1.25-micron tissue punch) using Western blot. Immunoblots showed labeling at around 97 and 210 kDa, which correspond to the monomer and dimer of mGluR2/3, respectively (Qian et al., 2018) .
Experiments
Time Course Study of the Effects of Poly(I:C). Ethanol na€ ıve rats (n = 29) were injected with poly(I:C) (0 or 3 mg/kg, IP). To examine the rapid consequences of poly(I:C) treatment, rats (n = 10 poly(I:C), n = 6 CON) were sacrificed 6 hours postinjection. The remaining rats were monitored daily until weights of the poly(I:C) group (n = 10) were no longer significantly different from the control group (n = 6). As such, rats were sacrificed 18 days post-poly(I: C) injection. Brain tissue was collected for RT-PCR analysis as described above.
Effects of Poly(I:C) on EtOH Self-Administration Following a Period Without Self-Administration. Figure 1A shows a timeline of this experiment. Self-administration trained rats were injected with poly(I:C) (0 or 3 mg/kg, IP, n = 8/group) and remained in the home cage for 18 days. During this time, rats were weighed daily and self-administration was withheld. Following this period, rats returned to self-administration training for 8 days.
Intersection of mGluR2/3 and the Effects of Poly(I:C) Treatment. Figure 1B shows a timeline of this experiment. Self-administration trained rats were injected with poly(I:C) (0 or 3 mg/kg, IP, n = 19 and 20/group, respectively) and remained in the home cage for 18 days. To test the effect of mGluR2/3 activation, rats were administered the mGluR2/3 agonist LY379268 (0, 3 mg/kg, IP, n = 26 and 13/group, respectively), 20 minutes prior to their first self-administration session following the 18 days in the home cage. To examine the effects of poly(I:C) on the expression of mGluR2/3, the following day, 10 rats (n = 5 saline/saline) and n = 5 (poly(I:C)/ saline) were sacrificed for mGluR2/3 immunohistochemistry. Immunohistochemistry analysis was used such that we could examine subregional mGluR2/3 expression (e.g., core vs. shell of the Acb; anterior IC).
Statistical Analyses
PCR results were assessed using 1-way analysis of variance (ANOVA) with treatment condition as the between groups factor. In addition, Pearson's correlations between gene expression levels for all genes within each brain region (IC or Acb) for each time point (6 hours or 18 days) were also computed. For self-administration experiments, EtOH lever responses, inactive lever responses, estimated EtOH intake (g/kg; estimated from the number of reinforcers received), and locomotor activity were analyzed with poly(I:C) dose and session as factors. We made the a priori decision to make comparisons between the poly(I:C) group and control for the first 2 sessions following poly(I:C) treatment. In addition, cumulative EtOH lever responses on the first 2 days postpoly(I:C) were analyzed with 2-way RM-ANOVA with dose and session time as factors. EtOH intake between doses for the first 2 sessions post-poly(I:C) was assessed with independent samples ttest. For the LY379268 experiment, t-tests were used to compare mGluR2/3-positive pixels/mm 2 between poly(I:C) and control for each brain region. In addition, EtOH lever responses, estimated EtOH intake (g/kg), and locomotor activity for this were assessed using 2-way ANOVA with poly(I:C) dose and LY379268 dose as factors. For each experiment, rat weights (grams) were recorded each day and were analyzed with 2-way RM-ANOVA with dose and day as factors. In all cases, post hoc analysis (Tukey) was used to determine specific differences between conditions. For all analyses, significance was set at 0.05.
RESULTS
Poly(I:C) Induces Time Point-Dependent Changes in Expression of Several Markers
To determine how TLR3 agonists alter gene expression in rat Acb and IC, 2 brain regions regulating EtOH self-administration, rats were treated with 3 mg/kg poly(I:C). As expected, an acute "sickness behavior" caused a transient loss of body weight. Mean weight change in the first 24 hours postinjection was +2.0 AE 0.8 (0.6%) and À13 AE 7.2 (À4.0%) grams for control and poly(I:C) groups, respectively. At 18 days post-poly(I:C) injection, weights did not differ between groups (control: 372 AE 18 grams; poly(I: C): 365 AE 17 g). We assessed both acute (e.g., 6 hours) and persistent (e.g., 18 days) mRNA changes including synaptic markers (mGluR, GLT1), as well as neuroimmune (TLR3, TLR7, and COX2) and trophic (BDNF) signals in the Acb and IC using RT-PCR. mRNA in the vehicle condition at the 2 time points did not differ and was pooled.
IC mRNA Analyses
As shown in Table 2 , there were significant changes in gene expression of mGluR2, mGluR3, TLR3, COX2, GLT-1, and BDNF in the IC following poly(I:C) administration. Post hoc analyses showed that at 6 hours postinjection with poly(I:C), there was a 10-fold increase in mGluR2, a 1.5-fold decrease in mGluR3, a 14-fold increase in TLR3, a 2-fold increase in COX2, a 2-fold increase in GLT1, and a 5.5-fold decrease in BDNF mRNA expression (p < 0.05). Eighteen days post-poly(I:C), there was a 1.3-fold increase in GLT1. At the 6-hour time point, TLR3 mRNA levels were positively correlated with increases in mGluR2 (r = 0.94, p < 0.001; Fig. 2A ), TLR7 (r = 0.57, p < 0.01), COX2 (r = 0.88, p < 0.001), and GLT1 (r = 0.63, p < 0.01), and TLR3 mRNA levels were correlated with decreases in levels of mGluR3 (r = À0.6, p < 0.05) and BDNF (r = À0.76, p < 0.05; Table 3 ). Eighteen days postinjection, TLR3 mRNA levels were positively correlated with mGluR2 (r = 0.61, p < 0.01; Table 4/ Fig. 2A ) and GLT1 (r = 0.68, p < 0.01; Table 4 ).
Acb mRNA Analyses
In the Acb, there were also significant poly(I:C)-induced changes in gene expression of mGluR2, mGluR3, mGluR5, TLR3, COX2, GLT1, and BDNF (see Table 5 ). Post hoc analyses showed, that 6 hours postinjection of poly(I:C), there was an 11-fold increase in mGluR2 and an almost 1-fold decrease in mGluR5, a 5.5-fold increase in TLR3, a 2.5-fold increase in COX2, and a 1.5-fold increase in GLT1 mRNA expression (p < 0.05). Eighteen days postinjection, Adult male Long Evans rats were treated with 3.0 mg/kg (IP) poly(I:C) or na€ ıve controls (CON) and then sacrificed either 6 hours or 18 days later. Dunnett post hoc t-test: *p < 0.05, **p < 0.01, relative to CON. Data are presented as mean % CON mRNA expression AE SEM.
there was a 1.7-fold increase in mGluR3, and a 2.4-fold increase in BDNF. At the 6-hour time point, TLR3 mRNA levels were positively correlated with increases in levels of mGluR2 (r = 0.99, p < 0.001; Fig. 2B ) and COX2 (r = 0.83, p < 0.001), and TLR3 levels were negatively correlated levels of mGluR5 (r = À0.60, p < 0.01; Table 6 ). At the 18-day time point (Table 7) , TLR3 mRNA levels were positively correlated with mGluR2 (r = 0.96, p < 0.001; Fig. 2B ), mGluR3 (r = 0.56, p < 0.01), TLR7 (r = 0.72, p < 0.001), COX2 (r = 0.85, p < 0.001), GLT1 (r = 0.75, p < 0.001), and BDNF (r = 0.55, p < 0.01).
Thus, the TLR3 agonist poly(I:C) rapidly increases mRNA expression of glutamatergic (mGluR2, GLT1) and neuroimmune (TLR3, COX2) targets in both the IC and Acb while decreasing trophic (BDNF) targets and mGluR5 only in the IC. Interestingly, the increased expression of glutamatergic (mGluR3, GLT1) targets persists for at least 18 days in the IC or Acb, while the trophic target (BDNF) recovers in IC, but is increased in Acb 18 days after poly(I:C).
TLR3 Agonist Poly(I:C) Increases EtOH SelfAdministration
To determine whether the persistent effects of poly(I:C) in IC and Acb were associated with changes in EtOH drinking behavior, rats with a history of EtOH self-administration were studied. Baseline EtOH self-administration prior to poly(I:C) injection is shown to the left of the axis break in Fig. 3A . There was no difference in self-administration on the baseline session between vehicle-and poly(I:C)-treated rats, t(10) = 0.075, n.s. The poly(I:C) group showed R-values of correlations in gene expression in insular cortex in rats that were treated with 3 mg/kg poly(I:C) and sacrificed 18 days later. *p < 0.01 or **p < 0.001, significantly correlated.
significant weight loss compared to control, confirming our findings from the time course experiment. Mean weight change in the first 24 hours postinjection was +2.0 AE 1.2 (+0.5%) and À20 AE 5.1 (À4.2%) grams for control and poly (I:C) groups, respectively. By 18 days post-poly(I:C), weights between poly(I:C) and saline-treated groups did not differ t(10) = 2.00, n.s. Eighteen days postinjection, weights were 372 AE 18 and 365 AE 17 grams for the control and poly(I:C) group, respectively.
There was a significant increase in EtOH self-administration in the poly(I:C) group once rats were returned to EtOH self-administration (Fig. 3) , whereas controls returned to previous baseline EtOH self-administration levels. There was a main effect of dose, F(1, 14) = 5.81, p < 0.05, and session, F(7, 98) = 2.90, p < 0.01, on TLR3 agonist-induced increases in EtOH lever responses. EtOH lever responses on the first and second sessions were significantly greater in the poly(I: C)-treated group compared to control, t(14) = 2.94, p < 0.05 and t(14) = 2.65, p < 0.05, respectively. Furthermore, EtOH lever responding on the first session was significantly greater in the poly(I:C)-treated rats compared to pre-poly(I:C) baseline, t(7) = 3.63, p < 0.05. Inactive lever responses were not affected by poly(I:C) treatment (Table 8) . Thus, in rats with a history of EtOH self-administration that were abstinent through the initial TLR3 agonist-induced "sickness-like behavior" increased EtOH self-administration upon the return to self-administration, whereas controls return to previous baseline response levels.
Analysis of the pattern of EtOH lever responding in the first 2 sessions showed that on the first session post-poly(I: C), there was a main effect of poly(I:C) treatment, F(1, 40) = 6.47, p < 0.05, with poly(I:C)-treated rats responding on the EtOH lever more than controls throughout the session (p < 0.05; Fig. 3B ) but not on the second session Adult male Long Evans rats were treated with 3.0 mg/kg (IP) poly(I:C) or na€ ıve controls (CON) and then sacrificed either 6 hours or 18 days later. Dunnett post hoc t-test: *p < 0.05, **p < 0.01, relative to CON. Data are presented as mean % CON mRNA expression AESEM. R-values of correlations in gene expression in nucleus accumbens in rats that were treated with 3 mg/kg poly(I:C) and sacrificed 6 hours later. *p < 0.01 or **p < 0.001, significantly correlated. R-values of correlations in gene expression in nucleus accumbens in rats that were treated with 3 mg/kg poly(I:C) and sacrificed 18 days later. *p < 0.01 or **p < 0.001, significantly correlated. Total Activity (Beam Breaks) Fig. 3 . Poly(I:C) increases alcohol self-administration following an 18-day period of abstinence. Following poly(I:C) treatment (3 mg/kg), alcohol lever responses (meanAESEM) were significantly higher than control and baseline on sessions 1 and 2 (A). Rats treated with poly(I:C) responded more throughout the first session following abstinence compared to controls (B). Alcohol intake (g/kg) was significantly higher on the first 2 sessions following 18 days in the home cage in the poly(I:C)-treated group (C/F). Total activity (beam breaks) was also significantly higher on the first 2 sessions in the poly(I:C) group (D/G). * p < 0.05, significantly different from control. + p < 0.05, significantly different from baseline. (Fig. 3E) . Furthermore, the poly(I:C) group showed significantly higher EtOH intake (g/kg) on both the first and second sessions (Fig. 3C, F) following 18 days in the home cage compared to controls, t(14) = 2.20, p = 0.05 and t (14) = 2.63, p < 0.05, respectively. In addition, locomotor activity was significantly higher in the poly(I:C)-treated rats on days 1 and 2 compared to saline (p < 0.05, Fig. 3D, G) , suggesting that poly(I:C)-treated rats maintained a heightened level of activity across the first 2 sessions. It is important to note though that this heightened level of activity did not increase nonspecific responding as inactive lever presses were not affected (Table 8 ). These findings suggest that TLR3 agonist treatment induces long-lasting changes that enhance EtOH self-administration.
TLR3 Agonist Induction of mGluR2/3 Expression and Enhanced mGluR2/3 Agonist Inhibition of Self-Administration
To determine whether the TLR3 agonist-induced changes in glutamatergic markers are related to EtOH self-administration, mGluR2/3 immunohistochemistry and the impact of the mGluR2/3 agonist LY379268 (3 mg/kg) post-poly(I:C) were assessed. As shown in Fig. 4A , the saline controls were not affected by mGluR2/3 activation. In contrast, in the poly (I:C) group, LY379268 treatment significantly reduced lever responses compared to both controls and poly(I:C) alone. For EtOH lever responses, there was a main effect of LY379268 dose, F(1, 35) = 14.424, p < 0.001, and a poly(I: C) dose by LY379268 dose interaction, F(1, 35) = 7.484, p < 0.05. Post hoc analysis showed that LY379268 significantly decreased EtOH responses in the poly(I:C)-treated rats (p < 0.001). Similarly, in assessing EtOH intake (g/kg), there was a main effect of LY379268 dose, F(1, 35) = 13.287, p < 0.001, and a poly(I:C) dose by LY379268 dose interaction, F(1, 35) = 5.948, p < 0.05. Post hoc analysis showed that EtOH intake in the poly(I:C)-treated rats was significantly decreased by LY379268 (p < 0.001). There were no significant effects of poly(I:C) or LY379268 on inactive lever responses or total activity (beam breaks) (Fig. 4B/Table 9 ). Figure 4C shows immunoblot labeling of the mGluR2/3 antibody that was used for immunohistochemistry. As shown in Fig. 4D ,E, mGluR2/3 protein expression as measured by immunohistochemistry was nearly doubled in AcbC compared to control, t(8) = 2.36, p < 0.05. Expression in Acb shell and IC did not differ between poly(I:C) and control. Together, these findings suggest that the persistent long-lasting induction of mGluR2/3 protein in the Acb following TLR3 activation, is related to the increase in EtOH self-administration and in turn, sensitizes response to the mGluR2/3 agonist (i.e., decrease in self-administration only in the poly(I:C)-treated group).
DISCUSSION
In this study, we evaluated the effects of the TLR3 agonist poly(I:C) on mRNA levels of neuroimmune genes (TLR3, TLR7, COX2) and glutamatergic genes (mGluR2, mGluR3, mGluR5, GLT1) along with the trophic factor BDNF, as well as the effects of TLR3 activation on operant EtOH self-administration. Our results indicate that acute activation of TLR3 via poly(I:C) induces rapid (6 hours postinjection) and long-term (18 days postinjection) changes in gene expression. In both IC and Acb, TLR3 agonist treatment rapidly (6 hours) increased mGluR2, TLR3, COX2, and GLT1, while decreasing BDNF mRNA in the IC and decreasing the predominantly postsynaptic-expressing mGluR3 and mGluR5 in the IC and Acb, respectively. BDNF, TLR3, and COX2 are expressed in neurons and glia (Bsibsi et al., 2002; Huang et al., 1987; Luo et al., 1998) and GLT1 in astrocytes (Rothstein et al., 1994) . mGluR2/3 is expressed in neurons (Jin et al., 2017; Luo et al., 1998; Ohishi et al., 1993; Tanabe et al., 1992) and typically provides negative feedback on glutamate synapses presynaptically, although mGlu3 has been found on glia as well (Aronica et al., 2003) . Additionally, in our previous studies we found EtOH-induced TLR3 expression in both neurons and microglia (Qin and Crews, 2012) . Together, the present findings suggest TLR3 agonist-induced alterations in mRNA and signaling across these brain regions, and likely across multiple cell types. Indeed, correlations between increased expression of TLR3 mRNA and mGluR2 mRNA among other genes are consistent with altered synaptic signaling. Additionally, treatment with the TLR3 agonist resulted in an increase in EtOH self-administration 18 days after injection, and increased sensitivity to mGluR2/3 activation-induced inhibition of drinking. Together, these findings suggest that TLR3 activation induces long-lasting changes in IC and Acb gene and protein expression that may be associated with potentiated alcohol self-administration. Mean AE SEM responses on the inactive lever for the 8 session post-poly(I:C). Inactive lever responses did not differ between the saline-and poly(I:C)-treated rats.
The mechanisms of TLR3-induced increases in gene expression and EtOH drinking are complex. Figure 5 depicts a possible mechanism for these TLR3-EtOH effects based on previous studies and our current findings. Moreover, emerging studies suggest endogenous TLR agonists in brain contribute to glial-neuronal plasticity (Crews et al., 2017b) . Previous studies have found poly(I:C) treatment in mice increases TNF-a in serum and brain, with the brain response persisting long after the serum response declines. Moreover, IL-6 and MCP1 levels were also increased in blood and brain by poly(I:C) (Qin and Crews, 2012) . In addition to TLR activation, EtOH exposure also increases TLR expression. EtOH pretreatment induces TLR3 and potentiates poly(I:C) response, consistent with EtOH increasing TLR3 signaling in the brain and periphery (Qin and Crews, 2012) . Furthermore, in vitro studies find both EtOH and poly(I:C) increase TLR3 mRNA in neuron-like cells (Lawrimore and Crews, 2017) , while emerging studies suggest endogenous TLR agonists in brain may contribute to EtOH induction of TLRs (Coleman and Crews, 2018; Coleman et al., 2017) . Importantly, poly(I:C) induction of brain TLR3 and other genes needs additional mechanistic studies to determine whether systemic responses have direct effects on brain (i.e., peripheral nerve activation of brain), as one would not expect large amounts of poly(I:C) to cross the blood-brain barrier (Table 7) . . Poly(I:C) alters mGluR2/3 expression and its behavioral effects are mitigated by mGluR2/3 activation. LY379268 (3 mg/kg) significantly decreased alcohol lever responses in poly(I:C)-treated rats, suggesting that mGluR2/3 activation counteracts the effects of poly(I:C). Alcohol intake (g/ kg) is denoted on each bar (A). Total activity (beam breaks) was not affected by poly(I:C) or LY379268 administration (B). mGluR2/3-specific staining was verified with Western blots, and the mGluR2/3 antibody was shown to label around 97 kDa and 210 kDa bands in striatal tissue, corresponding to the monomer and dimer of mGluR2/3, respectively (C). 18 days post-poly(I:C) treatment, the expression of mGluR2/3 is increased in nucleus accumbens core (AcbC), but not the shell (AcbSH) or insular cortex (D). Atlas images show where images for quantification were taken (D). Representative photomicrographs of AcbC following saline or poly(I:C) at 209 magnification (E). Arrows indicate example mGluR2/3 staining. Scale bars are 1000 lm. * p < 0.05, significantly different from control, # p < 0.05, poly(I:C)-treated rats significantly different from saline. [Color figure can be viewed at wileyon linelibrary.com] Glial-neuronal signaling regulates synapses through multiple mechanisms including synapse elimination and formation, changes in glial glutamate transporters, and gliotransmitter release processes. Poly(I:C) has been shown to increase hippocampal extracellular glutamate sensitizing mice to seizures (Hunsberger et. al., 2017) . Here, we found increased EtOH self-administration weeks after TLR3 agonist treatment on the same time scale with increased mRNA expression of mGluR3, GLT-1, and a 4-fold increase in mGluR2 (albeit a trend), and a significant increase in mGluR2/3 protein (quantified via immunohistochemistry) in AcbC. For the immunohistochemistry analysis, an antibody that labels both mGluR2 and 3 was used, and the observed poly(I:C)-induced increase in mGluR2/3 immunoreactivity in the AcbC was in animals with a history of EtOH selfadministration, which provides evidence of a glutamatergic adaptation within the context of EtOH self-administration. Furthermore, the expression of GLT1 was increased in both Acb and IC at 6 hours and 18 days later in the IC following poly(I:C). As both mGluR2 and GLT1 act to decrease glutamatergic transmission, this up-regulation may suggest the emergence of increased glutamatergic tone in the IC and Acb. Furthermore, as gene expression changes were the primary variable for these studies, it will be interesting for follow-up studies to measure protein expression for the targets. Together, these changes are relevant to EtOH self-administration as IC to AcbC projections have been shown to directly modulate EtOH drinking Seif et al., 2013) . Consistent with Acb, TLR3 contributing to drug reinforcement are studies finding transgenic mice lacking TLR3 or TLR3 inhibitors injected directly into Acb reduce cocaine conditioned place preference that is restored by selective viral expression of Acb TLR3 (Zhu et al., 2018) . In sum, these changes could represent increased glutamatergic signaling due to TLR3-induced plasticity. As such, the poly(I:C)-induced neuroimmune response through TLR3 promotes persistent changes in brain circuitry that are consistent with neuronal-glial signaling altering glutamatergic excitation through one or more of these mechanisms (Crews et al., 2017a; Haroon et al. 2017 ), which in turn may contribute to the escalations in EtOH self-administration.
Activation of TLRs has been shown to produce lasting increases in EtOH intake (Blednov et al., 2011) . In the current experiments, TLR3 activation by poly(I:C) significantly increased EtOH self-administration 18 days postinjection. This increase was the most dramatic on the first 2 sessions and was accompanied by a general increase in locomotor activity that was elevated in the poly(I:C)-treated rats through the second session. Following the second session, self-administration in the poly(I:C)-treated rats gradually returned to control levels. Interestingly, although TLR3 mRNA was elevated at 6 hours following poly(I:C) exposure, but not elevated at 18 days this pattern is consistent with a time-related loss of TLR3 sensitization that might be related to the decline in self-administration. It will be important for future studies to assess whether repeated administration of poly(I:C) would further potentiate these effects. In addition, studies using the bacterial endotoxin lipopolysaccharide (LPS), a potent agonist for TLR4 (Kawai and Akira, 2007) , have shown increases in home-cage EtOH intake more than a month after treatment (Blednov et al., 2011) , so it will be interesting for future studies to assess later time points to Fig. 5 . Hypothetical mechanism of poly(I:C)-TLR3 and ethanol (EtOH) exposure induced increases in nucleus accumbens excitation and responding for EtOH. TLR3 is expressed in both neurons and glia, and immune signaling is linked to astrocyte-neuronal increases in synaptic glutamate (Haroon, et. al. 2017) . Poly(I:C)-TLR3 activation can prime calcium signaling and release mechanisms (Park et al., 2016) . TLR3 activation in astrocytes increases intracellular calcium stimulating astrocyte exocytosis (Beckel et al., 2018) . Multiple studies have found Acb excitation is linked to increased operant responding for EtOH. We find poly(I:C) increases responding for EtOH and induces TLR3 mRNA as well as several proteins known to modulate glutamate synapses. Presynaptic mGLuR2 receptors regulate presynaptic glutamate release, and increased mGLuR2 mRNA is consistent with larger or more excitatory synapses. COX2 is expressed in astrocytes and increases PGE 2 that stimulates astrocyte glutamate release and reduces uptake by transporters increasing excitation (Sang et al., 2005) . The trophic factor BDNF is increased consistently with it promoting new excitatory synapse formation (Parkhurst et al., 2013) . Together, these changes are consistent with poly(I:C)-TLR3 signaling increasing EtOH responding through increases in glutamate synapse excitation. However, additional studies are needed to test these hypotheses. determine whether poly(I:C) is capable of producing such lasting changes. In addition, Blednov and colleagues (2011) showed that mice lacking a key component of TLR4, rendering it nonfunctional, did not show an increase in EtOH intake following LPS treatment.
Hypothetical Increase in Glutamate Excitation
An important consideration of the current experiments is time course. TLR3 systemic responses decline within 24 hours, whereas brain responses can persist for longer periods (Qin and Crews, 2012) . There is evidence for changes in sensitization of neuroimmune signals over time that mature. For example, negative affect used to model depression has been shown to emerge at later time points (for review, see Remus and Dantzer, 2016) . Our protocol used an extended period of abstinence, for example, 18 days, to allow initial sickness-like responses to subside and body weight to return to control levels. It is possible this home-cage abstinence acts as an "incubation period," contributing to increased selfadministration.
An important consideration for the current experiments is that these rats were all males. There is evidence that both acute and chronic EtOH intake induces greater TLR expression and signaling activity in TLR-related pathways in female mice compared to males (Fulham and Mandrekar, 2016; Wagnerberger et al., 2013) . Additionally, females (human and rodents) tend to show increased activation of proinflammatory response following TLR activation (for review see Klein and Flanagan, 2016) . Therefore, it will be interesting to determine whether there are sex differences in response to the poly(I:C)-induced changes in gene expression and selfadministration. Another consideration is that a sweetened EtOH reinforcer was used in the self-administration studies. LPS has been shown to decrease taste response to sucrose, an effect absent in TLR4-knockout mice (Zhu et al., 2014) . However, in the current experiments, poly(I:C) increased intake of the sweetened EtOH solution. Regardless, it will be important for future studies to assess whether these changes in self-administration following poly(I:C) are specific to EtOH or generalize to other drugs of abuse or nondrug reinforcers such as sucrose.
The current experiments show that TLR3 activation induces lasting changes at glutamatergic targets. As such, the final set of experiments sought to assess the impact of mGluR2/3 activation on EtOH self-administration following poly(I:C) treatment. Here, we show that the mGluR2/3 agonist LY379268 blocked the effects of TLR3 activation on EtOH self-administration, but did not affect self-administration on its own (Fig. 4A) . That is, following mGluR2/3 activation (poly(I:C)/LY379268 treated), self-administration was significantly decreased compared to poly(I:C)/saline or saline/LY379268-treated rats. Similar patterns of decreases in EtOH intake have been observed following mGluR2/3 activation in studies assessing EtOH dependence (Griffin et al., 2014; Windisch and Czachowski, 2018) . Moreover, saline-treated rats in the current experiments were not affected by treatment with LY379268, suggesting that it does not affect self-administration in control rats (non-poly(I:C)).
One limitation of this finding was that poly(I:C) did not significantly increase self-administration compared to saline in this experiment (trend for an increase p = 0.07; Fig. 4A ). Even with this consideration, the finding that LY379268 significantly decreased self-administration in the poly(I:C) group, but not the saline-treated group, suggests differential sensitivity to the agonist. This finding further supports that neuroimmune activation leads to increases in glutamatergic function that may affect sensitivity to EtOH, an effect that is ameliorated by mGluR2/3 activation.
Taken together, these findings demonstrate the functional impact of TLR3 neuroimmune activation on EtOH self-administration and the interaction with mGluR2/3. Numerous studies have suggested that neuroimmune activation may play an important role in the development of addiction (for review, see Coleman and Crews 2018) . Further, the identified interaction with mGlu2/3 is significant given the growing interest in mGluR2/3 as a therapeutic target of AUDs (Joffe et al., 2018) . Furthermore, EtOH induces many of the same effects in the brain that a viral pathogen would (i.e., increases in TLRs and other markers of inflammation Vetreno, 2014, 2016; Crews et al., 2013; Frank et al., 2015; Hutchinson et al., 2010; Knapp and Crews, 1999; McCarthy et al., 2018; Northcutt et al., 2015) . Based on these findings, future experiments should assess the effects of chronic TLR3 activation and the effects of activating other TLRs and potential interaction with mGluRs on EtOH self-administration, as gaining a better understanding of the underlying neurobiology of neuroimmune activation may ultimately lead to the development of more effective treatments for AUDs.
